Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.47 |
| ▸ | GBA1 | P04062 | 5/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | TNF | P01375 | 1/20 | 0.39 |
| ▸ | GJB2 | P29033 | 1/20 | 0.37 |
| ▸ | CETP | P11597 | 1/20 | 0.36 |
| ▸ | SELL | P14151 | 2/20 | 0.36 |
| ▸ | SELP | P16109 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4197225 | 1.00 | SLC2A1 (0.47) | SLC2A1GBA1MAPK1TNFGJB2 | |
| SCHEMBL28066824 | 0.88 | GBA1 (0.59) | SLC2A1GBA1MAPK1TNFGJB2 | |
| SCHEMBL27938366 | 0.88 | GBA1 (0.59) | SLC2A1GBA1MAPK1TNFGJB2 | |
| SCHEMBL28069563 | 0.88 | GBA1 (0.59) | SLC2A1GBA1MAPK1TNFGJB2 | |
| SCHEMBL28066817 | 0.88 | GBA1 (0.59) | SLC2A1GBA1MAPK1TNFGJB2 | |
| SCHEMBL9332917 | 0.88 | GBA1 (0.59) | SLC2A1GBA1MAPK1TNFGJB2 | |
| SCHEMBL28069583 | 0.88 | GBA1 (0.59) | SLC2A1GBA1MAPK1TNFGJB2 | |
| SCHEMBL16678919 | 0.84 | SLC2A1 (0.58) | SLC2A1GBA1MAPK1TNFGJB2 | |
| SCHEMBL16377619 | 0.83 | SLC2A1 (0.52) | SLC2A1GBA1MAPK1TNFGJB2 | |
| SCHEMBL14500937 | 0.83 | SLC2A1 (0.52) | SLC2A1GBA1MAPK1TNFGJB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090062214-A1 | Left-Side Glucose Lipid a Analogue | SANKYO COMPANY, LTD. (JP) | 2009-03-05 | — | — | US | disclosed |
| EP-1702926-A1 | LEVULOSE GLUCOSELIPID A ANALOGUE | Sankyo Company, Limited (JP) | 2006-09-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062214-A1 | Left-Side Glucose Lipid a Analogue | SLC2A3, GPR119, SLC2A2 | SLC2A1 6/4885GBA1 127/4885MAPK1 1294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.